OmniAb Names Amechi Nwachuku Chief Operating Officer
OmniAb, Inc. (NASDAQ:OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, announces that it has appointed Amechi Nwachuku to the newly-created position of Executive Vice President and Chief Operating Officer, effective today. Mr. Nwachuku will be primarily responsible for managing the strategy, operations and commercial maximization of xPloration®, OmniAb’s proprietary, innovative high-throughput single B-cell screening platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713808637/en/
Mr. Nwachuku has more than 25 years of experience, including leading multi-billion-dollar global life sciences tools businesses, with responsibility for driving commercial strategy, sales, marketing and integrated operations. Most recently, Mr. Nwachuku served as Vice President of Global Commercial Genetic Sciences at Thermo Fisher Scientific, and prior to that as Senior Vice President, Global Commercial, SCIEX at Danaher Corporation. Mr. Nwachuku also held senior executive roles within the Beckman Coulter Diagnostics business at Danaher and international leadership positions at Johnson & Johnson Diabetes Care and Bayer. Early in his career, he served as a management consultant at McKinsey & Company. He earned a Bachelor of Science in Chemical Engineering and his Master of Business Administration (MBA) from the Massachusetts Institute of Technology (MIT).
